Prediction of treatment outcomes in major depressive disorder
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Improving the treatment of major depressive disorder will require identification of moderators that predict differential outcomes across treatments at the level of the individual patient, referred to as precision medicine. Currently, there are no biological measures demonstrated to enhance treatment selection accuracy although there are some clinical variables that have prognostic value. Several recent studies comparing treatments with differing mechanisms of action have identified potential moderators that may eventually be used in precision medicine approaches. Genetic combination tests, systemic inflammation, electroencephalography and neuroimaging, in particular, show significant potential for near-term development as clinically meaningful moderators for use in treatment selection. Ultimately, combinations of moderators may provide the greatest level of precision in selecting optimal treatment approaches for individual depressed patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovering Endophenotypes for Major Depression
Hasler, G., Drevets, W. C., Manji, H. K., & Charney, D. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300506 · Cited by 1,123
Toward a Neuroimaging Treatment Selection Biomarker for Major Depressive Disorder
McGrath, C. L., Kelley, M. E., Holtzheimer, P. E., Dunlop, B. W., Craighead, W. E., Franco, A. R., Craddock, R. C., & Mayberg, H. S. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.143 · Cited by 561 · cited 1×
“Pretreatment hyperactivity (compared with whole brain mean metabolism) in this region predicted remission with SSRI pharmacotherapy and poor response to CBT, whereas hypoactivity predicted remission with CBT and poor response to SSRI pharmacotherapy [18].”
BackgroundSelf-citationUher, R., Tansey, K. E., Dew, T., Maier, W., Mors, O., Hauser, J., Dernovsek, M. Z., Henigsberg, N., Souery, D., Farmer, A., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14010094 · Cited by 418
Personalized Medicine for Depression: Can We Match Patients With Treatments?
Simon, G. E., & Perlis, R. H. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09111680 · Cited by 365 · cited 1×
“Understanding prediction treatment research requires distinguishing between nonspecific ‘predictors’, indicating likely outcome with a treatment, and ‘moderators’, which distinguish between outcomes with two different clinical treatment options [3].”
BackgroundSerotonin and emotional processing: does it help explain antidepressant drug action?
Harmer, C. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.036 · Cited by 219 · cited 1×
“Antidepressants act, at least in part, by reducing negative and increasing positive attentional biases [6].”
BackgroundKemp, A. H., Gordon, E., Rush, A. J., & Williams, L. M. (2008) · CNS Spectrums · doi:10.1017/s1092852900017120 · Cited by 170 · cited 1×
“Most published prediction studies report predictors associated with better or poorer response to a single treatment [4].”
BackgroundTreatment of depression with atypical features: a meta-analytic approach
Henkel, V., Mergl, R., Allgaier, A.-K., Kohnen, R., Möller, H.-J., & Hegerl, U. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2005.07.012 · Cited by 161 · cited 1×
“However, this moderator has little impact on modern psychiatric practice because the selective serotonin reuptake inhibitors (SSRIs) have proven to be as effective as monoamine oxidase inhibitors in the treatment of MDD, with lower treatment drop-out and better safety profile [7].”
BackgroundPretreatment Brain States Identify Likely Nonresponse to Standard Treatments for Depression
McGrath, C. L., Kelley, M. E., Dunlop, B. W., Holtzheimer III, P. E., Craighead, W. E., & Mayberg, H. S. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.005 · Cited by 139 · cited 1×
“This study also identified greater pretreatment resting state metabolism in the subcallosal cingulate cortex as predicting nonresponse to the combination of CBT with escitalopram [20].”
BackgroundSelf-citationDunlop, B. W., Binder, E. B., Cubells, J. F., Goodman, M. M., Kelley, M. E., Kinkead, B., Kutner, M., Nemeroff, C. B., Newport, D. J., Owens, M. J., et al. (2012) · Trials · doi:10.1186/1745-6215-13-106 · Cited by 136
Self-citationNeuroimaging-based biomarkers for treatment selection in major depressive disorder
Dunlop, B. W., & Mayberg, H. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/bdunlop · Cited by 127 · cited 2×
“Smaller hippocampal volume prior to treatment initiation has been associated with poorer response to pharmacotherapy [10], and hyper-responsiveness of the subgenual cingulate cortex to negatively valenced words has been replicated as a predictor of poorer response to cognitive behavioral therapy (CBT) [17].”
BackgroundSelf-citation
Cited by
Dunlop, B. W., Rajendra, J. K., Craighead, W. E., Kelley, M. E., McGrath, C. L., Choi, K. S., Kinkead, B., Nemeroff, C. B., & Mayberg, H. S. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050518 · Cited by 342
“Unfortunately, genetic testing, neuroimaging, and psychophysiological approaches, though promising, have not yet proven sufficiently accurate or replicable to warrant clinical application to individual patients (11).”
Self-citationBlood biomarkers and treatment response in major depression
Mora, C., Zonca, V., Riva, M. A., & Cattaneo, A. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1470927 · Cited by 107
“and error strategy [9]: this implies the lengthening of remission, patient’s suffering, poor compliance, appearance of treatment adverse effects, worsening of suicidal ideation, and high”
BackgroundFour Reasons Why Assisted Dying Should Not Be Offered for Depression
Blikshavn, T., Husum, T. L., & Magelssen, M. (2017) · Journal of Bioethical Inquiry · doi:10.1007/s11673-016-9759-4 · Cited by 60
“The same holds for predictors of treatment response in general, where there is a lack of consistent findings replicable across studies (Dunlop 2015).”
BackgroundMicroRNAs as critical biomarkers of major depressive disorder: a comprehensive perspective
Ortega, M. A., Alvarez-Mon, M. A., García-Montero, C., Fraile-Martinez, O., Lahera, G., Monserrat, J., Muñoz-Merida, L., Mora, F., Rodríguez-Jiménez, R., Fernandez-Rojo, S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9111659 · Cited by 57
“In this sense, further approaches are being under research to facilitate the diagnosis, prognosis and prediction of MDD, including various laboratory markers, genomics, proteomics, metabolomics and multiple biological components [19,172,173].”
MethodMoving pharmacoepigenetics tools for depression toward clinical use
Hack, L. M., Fries, G. R., Eyre, H. A., Bousman, C. A., Singh, A. B., Quevedo, J., John, V. P., Baune, B. T., & Dunlop, B. W. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.02.009 · Cited by 33
Self-citation
Metadata
- Authors
- Dunlop, B. W.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2015-08-02
- Volume
- 8
- Issue
- 6
- Pages
- 669-672
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W1763310011
- Cited by
- 22
- References
- 10
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prediction of treatment outcomes in major depressive disorder. https://app.cochat.ai/papers/10.1586/17512433.2015.1075390
- The paper
- Dunlop, B. W. (2015). Prediction of treatment outcomes in major depressive disorder. Expert Review of Clinical Pharmacology. https://doi.org/10.1586/17512433.2015.1075390
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.